Omega XL Reports New Independent Study: Omega-3s May Benefit Children With ADHD

The results of a recent randomized controlled trial, published in the journal Nutrition, demonstrated that omega-3 fatty acids EPA and DHA, such as found in Omega XL®, benefit cognition and behavior in children with attention-deficit / hyperactivity disorder (ADHD).

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
data lead researchers to conclude that omega-3 polyunsaturated fatty acids, specifically DHA, may improve literacy and behavior in children with ADHD

Fort Lauderdale, FL (PRWEB) July 03, 2012

Sixty-percent of the human brain is composed of fat. Over half of that fat is omega-3, predominantly DHA. It is generally hypothesized that many brain conditions could be a result of a deficiency in these essential fats. The objective of this randomized controlled trial was to determine the effects of omega-3 DHA and EPA, such as found in Omega XL® by Great HealthWorks, on literacy and behavior in children with attention-deficit / hyperactivity disorder (ADHD).

Ninety Australian children 7 to 12 years old, with ADHD symptoms higher than the 90th percentile on the Conners Rating Scales, were given an omega-3 DHA/EPA supplement or a placebo. After four months the effects of omega-3 supplementation on cognition, literacy, and parent-rated behavior were assessed.

Subsequent examination of the children’s fatty acid profiles indicated that an increased proportion of DHA was associated with improved word reading and lower parent ratings of oppositional behavior. These effects were more evident in a subgroup of 17 children with learning difficulties: increased DHA was associated with improved word reading, improved spelling, an improved ability to divide attention, and lower parent ratings of oppositional behavior, hyperactivity, restlessness and overall ADHD symptoms.

These data lead researchers to conclude that omega-3 polyunsaturated fatty acids, specifically DHA, may improve literacy and behavior in children with ADHD. The greatest benefit may be observed in children who have learning difficulties in conjunction with ADHD.

Omega XL is one of only two Omega 3 supplements sold in the world that contains the patented stabilized marine lipid extract PCSO-524™ derived only from the New Zealand green-lipped mussel, with 30 healthy fatty acids including DHA and EPA. Sold in other parts of the world under its sister brand name Lyprinol, Omega XL is manufactured exclusively by Great HealthWorks Inc., and is the most widely available omega-3 fish oil supplement containing the potent PCSO-524™ marine lipid extract. To find more information about Omega XL and PCSO-524™ visit http://www.OmegaXL.com

Source: Journal Nutrition
2012 Jun;28(6):670-7. Epub 2012 Apr 25.
Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit / hyperactivity disorder: a randomized controlled trial.
Milte CM, Parletta N, Buckley JD, Coates AM, Young RM, Howe PR.
Nutritional Physiology Research Centre, University of South Australia, Adelaide, South Australia, Australia.
(http://www.ncbi.nlm.nih.gov/pubmed/22541055)

About Great HealthWorks, Inc.
Great HealthWorks, founded in 2003, is a global manufacturer and distributor of one-of-a-kind, natural products. Great HealthWorks, the makers of Omega XL®, an all-natural, highly purified marine lipid extract from the green-lipped mussel (Perna Canaliculus) known as PCSO-524™. This patented marine lipid complex comes exclusively from the pristine waters of the Marlborough Sounds in New Zealand, and contains 30 healthy fatty acids. Great HealthWorks corporate headquarters and distribution center are in Hollywood, Florida. To find out more about Great HealthWorks, visit http://www.GreatHealthWorks.com. And for more information about the benefits of Omega XL, visit http://www.OmegaXL.com. Join the conversation: http://www.facebook.com/myomegaxl


Contact